Company Profile
Shanghai INT Medical Instruments Co., Ltd. (brand name: INT Medical) is a China-based manufacturer of interventional medical devices, headquartered in Jiading District, Shanghai. Founded in 2006 and originally established as Shanghai Kandelai Medical Instruments Co., Ltd., the company was listed on the Hong Kong Stock Exchange Main Board (HKEX: 01501) in November 2019. INT Medical operates 24 subsidiaries and maintains three manufacturing bases in Shanghai, Zhuhai (Guangdong), and Rizhao (Shandong), employing over 2,000 people globally.
Core Products ＆ Technologies
Cardiovascular Interventional Access ＆ Therapeutics
• Balloon Inflation Devices: Balloon expansion pressure pumps for PCI and peripheral angioplasty procedures
• Catheter Sheath Kits: Introducer sheaths and dilators for vascular access in interventional cardiology
• Angiographic Wires ＆ Catheters: Diagnostic guidewires and angiography catheters for coronary and peripheral imaging
• PTCA Balloon Dilatation Catheters: Percutaneous transluminal coronary angioplasty balloons for lesion dilatation
Peripheral Vascular ＆ Endovascular Solutions
• Peripheral Balloons ＆ Microcatheters: Balloon dilatation catheters, support catheters, and microcatheters for peripheral artery disease
• Thrombus Aspiration Systems: Mechanical thrombectomy and circulation support devices for vascular occlusion
• Aortic Endografts (via Weiqiang Medical acquisition): WeFlow-Tbranch fenestrated thoracic stent graft system, Fabulous aortic stent graft system, ZIPPER integrated aortic arch stent graft system, and Grency® iliac vein stent for thoracic, abdominal, and venous repair
Neurovascular, Electrophysiology ＆ Non-Vascular
• Neurovascular Devices: Embolic protection and delivery systems for cerebral vascular interventions via Shanghai Puhui Medical subsidiary
• Cardiac Electrophysiology (via Deno EP acquisition): Access and delivery tools for arrhythmia and structural heart procedures; acquisition of Deno Electrophysiology Medical control rights approved at 2026 shareholder meeting
• Urological Interventional Products: Minimally invasive devices for urinary tract procedures via Shandong INT Medical subsidiary
Market Position ＆ Certifications
INT Medical holds a leading position in China's domestic interventional access device market, competing with Terumo, Medtronic, Boston Scientific, Abbott, and MicroPort Scientific. Key strengths include:
• 20 years of interventional device manufacturing heritage
• Full-chain capability: In-house mold development, R＆D, equipment manufacturing, and self-operated sterilization (EO sterilization center)
• Regulatory compliance: ISO 13485 certified, CE marked, and FDA cleared products; 45 Class III NMPA registrations, 75 Class II NMPA registrations, 43 CE certifications, and 26 FDA approvals as of December 2025
• Intellectual property: 734 granted patents and 237 pending applications globally
• National recognition: Designated as a national-level "Little Giant" enterprise and National Intellectual Property Advantage Enterprise; selected for S＆P Global Sustainability Yearbook (China Edition) for two consecutive years since 2024
Corporate Timeline
2006 — Founded in Shanghai as Shanghai Kandelai Medical Instruments Co., Ltd.
2018 — Established Shanghai Qimu Medical Co., Ltd. for peripheral vascular devices; established Shanghai Puhui Medical for neurovascular layout
2019 — Listed on the Hong Kong Stock Exchange Main Board under stock code 01501.HK
2021 — Established Shandong INT Medical Co., Ltd. to expand into urological interventional products
2022 — Established Shanghai INT Biotechnology Co., Ltd. for neurovascular R＆D
2024 — Recognized in S＆P Global Sustainability Yearbook (China Edition); annual revenue exceeded RMB 850 million
2025 — Acquired Weiqiang Medical (唯强医疗) for RMB 513 million, adding aortic endograft and high-value vascular portfolios; completed H-share placement raising over HKD 900 million; invested RMB 100 million in Chenyao Xinchen Fund for medical device equity investments; revenue reached RMB 1.065 billion with net profit of RMB 233 million
2026 — Announced proposal to acquire Valgen Holding Corporation (parent of Hangzhou Dejin Medical / Valgen Medtech) up to 90% equity for no more than RMB 1.5 billion, entering structural heart disease segment; announced proposal to acquire control of Hangzhou Deno Electrophysiology Medical; disclosed proposal to abolish Board of Supervisors and amend Articles of Association; scheduled 2026 annual general meeting for May 28
Target Markets ＆ Applications
• Coronary Interventions (PCI): Diagnostic and therapeutic devices for percutaneous coronary angioplasty and stent delivery
• Peripheral Artery Disease (PAD): Balloons, stents, and thrombectomy systems for lower limb and visceral artery revascularization
• Aortic ＆ Structural Heart Disease: Endovascular repair solutions for thoracic and abdominal aortic aneurysms, and transcatheter valve repair via proposed Dejin acquisition
• Neurovascular ＆ Electrophysiology: Access and delivery systems for cerebral and cardiac electrophysiology procedures
• Non-Vascular Urology: Interventional devices for minimally invasive urinary tract treatments
Contact Information
Global Headquarters
Address: Building 2, No. 925 Jinyuan 1st Road, Jiading District, Shanghai, China
Phone: +86 21 5914 0056
Website: www.int-medical.com
Hong Kong Office
Address: 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
